학술논문
The booster dose of BNT162b2 mRNA vaccine in patients after hematopoietic stem cell transplantation: humoral and clinical response and serological conversion predictors.
Document Type
Letter to the Editor
Author
Source
Subject
*FLOW cytometry
*COVID-19
*HOMOGRAFTS
*GRAFT versus host disease
*COVID-19 vaccines
*HEMATOPOIETIC stem cell transplantation
*IMMUNOSUPPRESSIVE agents
*POLYMERASE chain reaction
*ANTIGENS
*
*
*
*
*
*
*
*
Language
ISSN
0284-186X
Abstract
The article focuses on the effectiveness of the BNT162b2 mRNA vaccine's booster dose in hematopoietic stem cell transplantation (HSCT) patients. Topics include the clinical response to the booster dose, predictors of serological conversion, and the impact of the booster dose on antibody concentration and COVID-19 incidence among HSCT patients.